Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule therapeutic addressing the under-served market of painful diabetic neuropathy.

The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy will evaluate the efficacy, safety and tolerability of three dose levels of AEG33773 in diabetic patients suffering from significant neuropathic pain. This study is underway in Canada and Aegera will soon initiate trial sites in the Unites States, where the IND has recently cleared the FDA regulatory review process, and also in Europe, where the regulatory documents are now under review by the appropriate regulatory authorities.

"We are very excited about this first Phase 2 study for AEG33773 which has demonstrated robust preclinical in vivo data in multiple models of neuropathic and inflammatory pain. Furthermore, AEG33773 could have the potential to treat chronic pain conditions well beyond painful diabetic neuropathy." commented Dr. Jacques Jolivet, M.D., Senior Vice President Clinical Development of Aegera.

"With the successful conclusion of the Phase 1 safety studies for AEG33773 and the initiation of the first Phase 2a trial in diabetic patients suffering from significant neuropathic pain, we are now focused on successfully completing this trial while identifying an appropriate development partner; this will ensure that our novel agent is developed rapidly and effectively for its first indication while exploring additional indications so as to expand this franchise on a global basis." added Dr. Michael J. Berendt, Aegera's President and CEO.

About Aegera Therapeutics Inc. (www.aegera.com'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Ras Al Khaimah, UAE (PRWEB) October 22, 2014 ... in game-changing life science and healthcare projects, announces the ... MBBS MRCGP DRCOG DCH to its advisory team. Dr. ... research advisory team. , A graduate of ... Dr. Siddiqui was subsequently degreed in medicine in 2001. ...
(Date:10/22/2014)... 2014 Nuvilex, Inc. (OTCQB: NVLX) – According ... worldwide are living with diabetes, with  that number expected ... global market for diabetes treatments is approximately $500 billion.  ... died from pancreatic cancer.  Pancreatic cancer is the fourth ... the United States , and according ...
(Date:10/20/2014)... 20, 2014 Convey Computer , ... team from Iowa State University won first place in ... a Convey HC-2ex, the team’s solution achieved the highest ... than the second place finisher. , Experts from all ... the month long challenge, using a variety of design ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... 2011 Bacterin International Holdings, Inc. ... development of revolutionary bone graft material and anti-infective coatings for ... The record month reflects both greater capacity and efficiency in ... new hires and a management reorganization completed during the month. ...
... 5, 2011   Medical devices ... underlying sales growth of 5%. In an interview ... talks Q2 results and introduces his plans for a new ... focus on emerging markets.  Bohuon also announced plans ...
... can make graphene out of just about anything with carbon -- ... University lab of chemist James Tour proved it when they invited ... them how it,s done. The work is part of a ... described how graphene -- a single-atom-thick sheet of the same material ...
Cached Biology Technology:Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July 2Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July 3Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July 4Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July 5Bacterin Reports New Hires and Management Reorganization, Driving Most Active Processing Month in July 6One box of Girl Scout Cookies worth $15 billion 2
(Date:10/15/2014)... 2014   Neurotechnology , a provider of ... of the VeriLook Surveillance 3.0 software development ... biometric face identification using live video streams from ... new version not only identifies faces in a ... while they are moving through the video frame. ...
(Date:10/14/2014)... sequenced the house fly genome for the first time, ... an insect that thrives in pathogen-rich dung piles and ... the journal Genome Biology , will increase understanding ... flies quickly adapt to resist insecticides, which could lead ... domestica) carry and transmit more than 100 human and ...
(Date:10/14/2014)... – Scientists from The Scripps Research Institute (TSRI) have ... Health (NIH) to lead an investigation of Lassa fever ... Africa. The study aims to understand how Lassa fever ... others survive the inflection. , "The ultimate goal ... how Lassa fever virus causes disease and develop new ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... , , , , ... AUDIO: Falon Tilley and Michael W. Beets discuss the successful implementation of ... Click here for more information. , , ... , , , , , ...
... by Jonathan Waxman is a collection of short stories that ... a doctor,s life before the dawn of management. Written in ... from the author,s decades of clinical experience. Chutney Wars, The ... a few of the chapters in this engagingly written book. ...
... have been awarded fellowships from the Alfred P. ... NYU,s Center for Neural Science, and Nicholas Stavropoulos, ... NYU Langone Medical Center and its Neuroscience Institute. ... and scholars "whose achievements and potential identify them ...
Cached Biology News:Healthy Lunchbox Challenge helps influence healthy eating habits in children 2Healthy Lunchbox Challenge helps influence healthy eating habits in children 3Healthy Lunchbox Challenge helps influence healthy eating habits in children 4Two NYU faculty win Sloan Foundation research fellowships 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... 100-120 and 220-240 V, is a microfluidics-based ... gel-based electrophoresis, including some data analysis, in ... for protein analysis (it does not include ... The system includes the electrophoresis station, priming ...
...
... Grace's medium was originally formulated to ... the Australian emperor gum moth,Antherea eucalypti. The ... to more closely resembleAnthereahemolymph. The cell lines ... the first continuous lines developed. The basal ...
Biology Products: